Rezera Inc.

expected

Not yet set

status

Filed with SEC

proposed ticker

RZRA

Industry

Pharmaceutical Preparations

Headquarters

United States

Incorporated in

Underwriters (from filing)

Jefferies LLC, TD Securities (USA) LLC, Cantor Fitzgerald & Co, Wedbush Securities Inc

Overview

— AI-generated from the filing, see note below

Business overview

Rezera Inc. is a clinical-stage biotechnology company focused on developing proprietary oral inhibitors of the NOD-like receptor protein 3 (NLRP3), which is involved in sterile inflammation. Their lead product candidate, ruvonoflast, targets NLRP3 activation to potentially reduce inflammation-related diseases such as cardiovascular and neuroinflammatory conditions. The company aims to demonstrate that ruvonoflast acts as a disease-modifying anti-inflammatory therapy in peripheral artery disease (PAD), affecting approximately 20 million adults in the U.S. with significant unmet medical needs and high healthcare costs.

Revenue model

Not disclosed in the provided filing text.

Competitive strengths

Proprietary oral inhibitors targeting NLRP3
Historical leadership in NLRP3 research and development
Well-tolerated candidate in human clinical trials
Potential for broad tissue distribution of lead product candidate

Risk factors

Dependence on the success of clinical trials for ruvonoflast
Inability to achieve regulatory approvals
Competition from established treatments and development of new therapies
Unpredictability of future financial results

Use of proceeds

Not disclosed in the provided filing text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

The proposed ticker is RZRA. Underwriters on the deal include Jefferies LLC, TD Securities (USA) LLC, Cantor Fitzgerald & Co, Wedbush Securities Inc. Rezera Inc. is headquartered in United States and incorporated in DE. It is classified under Pharmaceutical Preparations.

Related IPO lists

Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Rezera Inc..

Biotech IPOs United States IPOs Jefferies LLC IPOs TD Securities (USA) LLC IPOs Cantor Fitzgerald & Co IPOs

Embed this company

Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.

Iframe — WordPress / Ghost / Notion / Webflow

<iframe src="https://www.discoveripo.com/embed/rezera" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Rezera Inc. — DiscoverIPO"></iframe>

Dark by default. For a light background, use https://www.discoveripo.com/embed/rezera?theme=light as the src instead.

Share image — Substack, email, anywhere

https://www.discoveripo.com/ipo/rezera/opengraph-image

Attribution text

Rezera Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/rezera?utm_source=embed&utm_medium=text&utm_campaign=rezera

Track this IPO

Get emailed when Rezera Inc.'s terms, price, or expected date change — no weekly noise, just this company.

Frequently asked questions

What is Rezera Inc.'s ticker symbol?

Rezera Inc.'s proposed ticker is RZRA.

Where this data comes from

Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Nov 5, 2026.

View the original filing on SEC EDGAR →

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.